A Phase 2 interventional study of pemetrexed and carboplatin in Non Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 7 sites in France. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2010-10-13.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.
Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 114th largest by enrollment of the 223 interventional ones that give a count, is one of 25 that started in 2006, is one of 128 in phase 2, and was the 37th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
Guangzhou Medical University · Sites in China
Ages 18–75
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18–85
Shanghai Chest Hospital · Sites in China
Ages 18+
Taipei Veterans General Hospital, Taiwan · Sites in Taiwan
Ages 20+
By country, each count listing its studies:
Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 70 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
227 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 148 · Phase 3 47 · Phase 4 8
First in 2001; this study’s year is marked. 25 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 62 is close to the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 64 across the 223 interventional studies. Of the 161 that completed or were terminated, 89 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 227 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 96th largest by enrollment of the 139 interventional ones that give a count, is one of 10 that started in 2006, is one of 73 in phase 2, and was the 39th registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
7 of the studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT03178552Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | 2027-06-30 |
| NCT05805631Taipei Veterans General Hospital, TaiwanIntrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC | 2026-12-31 |
| NCT06440954Hunan Province Tumor HospitalEfficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
A phase II study to evaluate the efficacy and safety profile of the combination of Pemetrexed and Carboplatin in elderly patients with advanced non-small cell lung cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pemetrexed: 500 milligrams per square meter (mg/m\^2), intravenous (IV), every 21 days x 6 cycles. Carboplatin: Area Under the Curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles.
Drug: pemetrexed · Drug: carboplatin
500 milligrams per square meter (mg/m\^2), intravenous (IV), every 21 days x 6 cycles
Also known as: LY231514, Alimta
Area Under the Curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
Percentage of Participants With a Complete or Partial Tumor Response (Overall Tumor Response)
Tumor response is defined as the percentage of patients with either a complete response or a partial response. Response was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions and Partial Response=30% decrease in sum of longest diameter of target lesions.
Time frame: baseline to measured objective tumor response (up to six 21-day cycles)
Time to Treatment Failure
Defined as the time from study enrollment to the first observation of disease progression, death as a result of any cause, or early discontinuation of treatment. Time to treatment failure was censored at the date of the last follow-up visit for patients who did not discontinue early, who were still alive, and who have not progressed.
Time frame: baseline to stopping treatment (up to six 21-day cycles)
Overall Survival
Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.
Time frame: baseline to date of death from any cause (up to 14.5 months)
Estimated Probability of One Year Progression-free Survival
Progression free survival (PFS) is the duration from enrollment until first disease progression or death. For patients not known to have died as of the data cut-off date and who do not have progressive disease, PFS is censored at the last radiological assessment date.
Time frame: baseline to measured progressive disease or death, 1 year
Time to Treatment Failure
Defined as the time from study enrollment to the first observation of disease progression, death as a result of any cause, or early discontinuation of treatment. Time to treatment failure was censored at the date of the last follow-up visit for patients who did not discontinue early, who were still alive, and who have not progressed.
Time frame: baseline to stopping treatment (up to six 21-day cycles)
| Milestone | Pemetrexed + Carboplatin |
|---|---|
| Started | 62 |
| Completed | 29 |
| Not completed | 33 |
| Withdrew: Adverse event | 11 |
| Withdrew: Death from study disease | 1 |
| Withdrew: Death from study drug toxicity | 1 |
| Withdrew: Death not study drug related | 2 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Withdrawal by subject | 4 |
| Withdrew: Physician decision | 2 |
| Withdrew: Lack of efficacy | 11 |
Tumor response is defined as the percentage of patients with either a complete response or a partial response. Response was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions and Partial Response=30% decrease in sum of longest diameter of target lesions.
| percentage of participants | Pemetrexed + Carboplatin |
|---|---|
| Percentage of Participants With a Complete or Partial Tumor Response (Overall Tumor Response) | 28.6 (16.58 to 43.26) |
Defined as the time from study enrollment to the first observation of disease progression, death as a result of any cause, or early discontinuation of treatment. Time to treatment failure was censored at the date of the last follow-up visit for patients who did not discontinue early, who were still alive, and who have not progressed.
| weeks | Pemetrexed + Carboplatin |
|---|---|
| Time to Treatment Failure | 12.95 ± 0.74 |
Defined as the time from study enrollment to the first observation of disease progression, death as a result of any cause, or early discontinuation of treatment. Time to treatment failure was censored at the date of the last follow-up visit for patients who did not discontinue early, who were still alive, and who have not progressed.
| weeks | Pemetrexed + Carboplatin |
|---|---|
| Time to Treatment Failure | 16.0 (10.1 to NA) |
Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.
| months | Pemetrexed + Carboplatin |
|---|---|
| Overall Survival | 10.4 (9.1 to 12.9) |
Progression free survival (PFS) is the duration from enrollment until first disease progression or death. For patients not known to have died as of the data cut-off date and who do not have progressive disease, PFS is censored at the last radiological assessment date.
| percentage of patients | Pemetrexed + Carboplatin |
|---|---|
| Estimated Probability of One Year Progression-free Survival | 13.1 (4.6 to 21.6) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed + Carboplatin | — | 26/62 (41.9%) | 61/62 (98.4%) |
| Event | Pemetrexed + Carboplatin |
|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 6/62 |
| AnaemiaBlood and lymphatic system disorders | 4/62 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/62 |
| General physical health deteriorationGeneral disorders | 4/62 |
| NeutropeniaBlood and lymphatic system disorders | 3/62 |
| DiarrhoeaGastrointestinal disorders | 3/62 |
| SepsisInfections and infestations | 2/62 |
| Bone marrow failureBlood and lymphatic system disorders | 1/62 |
| Febrile bone marrow aplasiaBlood and lymphatic system disorders | 1/62 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/62 |
| Event | Pemetrexed + Carboplatin |
|---|---|
| NeutropeniaBlood and lymphatic system disorders | 44/62 |
| AstheniaGeneral disorders | 42/62 |
| AnaemiaBlood and lymphatic system disorders | 35/62 |
| ThrombocytopeniaBlood and lymphatic system disorders | 29/62 |
| AnorexiaMetabolism and nutrition disorders | 25/62 |
| Weight decreasedInvestigations | 23/62 |
| ConstipationGastrointestinal disorders | 21/62 |
| NauseaGastrointestinal disorders | 21/62 |
| VomitingGastrointestinal disorders | 14/62 |
| LeukopeniaBlood and lymphatic system disorders | 12/62 |
| Age Continuous(years) | Pemetrexed + Carboplatin |
|---|---|
| Mean | 76.5 ± 3.6 |
| Sex: Female, Male(Participants) | Pemetrexed + Carboplatin |
|---|---|
| Female | 11 |
| Male | 51 |
| Region of Enrollment(participants) | Pemetrexed + Carboplatin |
|---|---|
| France | 62 |
| Disease Stage(participants) | Pemetrexed + Carboplatin |
|---|---|
| Stage IIIB | 13 |
| Stage IV | 49 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | Pemetrexed + Carboplatin |
|---|---|
| 0 - Fully Active | 10 |
| 1 - Ambulatory, Restricted Strenuous Activity | 52 |
| Pathological Diagnosis(participants) | Pemetrexed + Carboplatin |
|---|---|
| Large Cell Lung Cancer | 5 |
| Adenocarcinoma of Lung | 32 |
| Squamous Cell Carcinoma of Lung | 21 |
| Other: Carcinoma-Infiltrant Indifferencie | 1 |
| Other: Carcinoma | 1 |
| Other: Indifferencied Non-Small Cell Lung Cancer | 1 |
| Other: Undifferentiated | 1 |
The record gives a start of Aug 2006, a primary completion of Nov 2008 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pemetrexed · Carboplatin
Carcinoma, Non-Small-Cell Lung →